3 July 2019 - - US-based clinical-stage biotechnology company Viela Bio has appointed Mitchell Chan as chief financial officer, the company said.
In this role, he will be responsible for leading corporate financing, financial operations, treasury, investor relations, corporate communications and corporate strategy.
Previously, Chan served as Viela's vice president, head of finance and corporate strategy.
Chan has more than 15 years of finance experience. Prior to joining Viela in 2018, he served as director of Investor Relations for AstraZeneca, North America.
Previously, Chan held various roles of increasing responsibility at Genentech-Roche, including in BioOncology Commercial Finance, R and D Finance, and Mergers and acquisitions.
Chan is the recipient of Executive Certifications from Stanford University, University of California, and University of Pennsylvania (Wharton) and earned his BSc, MSc and MBA (Rotman School of Management) from the University Toronto.
Viela Bio, headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease.